November 10, 2022

TO:  Hospitals, Local Health Departments, Laboratories, Emergency Rooms, Family Medicine, Pediatrics, Adolescent Medicine, Infectious Disease, Neurology, Infection Control practitioners, and Primary Care Providers

FROM: New York State Department of Health (NYSDOH) Bureau of Communicable Disease Control (BCDC), New York City Department of Health and Mental Hygiene

HEALTH ADVISORY: INCREASED RESPIRATORY VIRUS ACTIVITY, ESPECIALLY AMONG CHILDREN

SUMMARY

- The Centers for Disease Control and Prevention (CDC) issued a Health Alert Network (HAN) Health Advisory about earlier than expected elevated respiratory disease incidence caused by multiple viruses occurring especially among children, which is placing strain on healthcare systems. This HAN can be found at the end of this document.

- Co-circulation of respiratory syncytial virus (RSV), influenza viruses, SARS-CoV-2, and other respiratory viruses is placing stress on healthcare systems this fall and may continue to do so this winter. This early increase in disease incidence highlights the importance of optimizing respiratory virus prevention and treatment measures, including prompt vaccination and testing, masking in crowded indoor areas, practicing good hand hygiene, staying home when sick, and antiviral treatment when appropriate.

- Respiratory syncytial virus (RSV) typically increases in circulation between October and May. This year, as in 2021, case numbers increased earlier than usual in New York, and levels are already exceeding seasonal peaks typically seen later in the RSV season.

- Influenza season also typically occurs between October and May. This year there is an early increase in flu activity. The most commonly detected influenza virus nationwide is influenza A(H3N2); in New York, a mix of influenza A H3 and H1 has been detected thus far. Most reported infections are in children and young adults.

- COVID-19 community levels can be more difficult to track given the limited reporting of at-home testing, but nationwide hospitalization rates in children younger than 6 months continue to be concerning. In New York, the highest rates of COVID-19 hospitalizations occur among those age 65 and over and among unvaccinated individuals. Limited uptake of bivalent boosters and spread of new variants may lead to increasing levels of SARS-CoV-2 this fall and winter.

- In September, CDC distributed an advisory regarding a nationwide increase in pediatric hospitalizations in patients with severe respiratory illness who also tested positive for rhinovirus (RV) and/or enterovirus (EV). Some specimens have been positive for enterovirus D68 (EV-D68). Since September, enterovirus detections in New York State have decreased.
Although it primarily causes acute respiratory illness, EV-D68 has been associated with acute flaccid myelitis (AFM), a rare but serious neurologic complication involving limb weakness. AFM and paralytic polio can have similar clinical presentations; specimens tested at Wadsworth Center for pathogens that can cause AFM will also be tested for poliovirus.

**REPORTING: Severe Respiratory Infections**
Healthcare providers should report clusters of severe respiratory illness to their local health department (LHD); this includes reporting clusters of severe respiratory illness in pediatric patients where EV-D68 infection is known or suspected. Reporting should be to the county health department where the patient resides.

Clusters among New York City residents should be reported to the NYC Health Department Provider Access Line (PAL) at 866-692-3641. Outside of New York City, contact information is available at: [https://www.health.ny.gov/contact/contact_information](https://www.health.ny.gov/contact/contact_information).

If you are unable to reach the LHD where the patient resides, please contact the NYSDOH Bureau of Communicable Disease Control at 518-473-4439 during business hours or 866-881-2809 evenings, weekends, and holidays.

**ADDITIONAL RESOURCES**

- NYSDOH June 2022 AFM HAN: [https://apps.health.ny.gov/pub/ctrldocs/alrtview/postings/NYSDOH_AFM_Health_Advisory_06242022_FINAL_1656100564923_0.pdf](https://apps.health.ny.gov/pub/ctrldocs/alrtview/postings/NYSDOH_AFM_Health_Advisory_06242022_FINAL_1656100564923_0.pdf)
- NYSDOH Wadsworth Virology: [https://www.wadsworth.org/programs/id/virology](https://www.wadsworth.org/programs/id/virology)
- NYC DOHMH Influenza: [https://www.nyc.gov/site/doh/providers/health-topics/flu-alerts.page](https://www.nyc.gov/site/doh/providers/health-topics/flu-alerts.page)
- NYC DOHMH RSV: [https://www.nyc.gov/site/doh/health/health-topics/respiratory-syncytial-virus.page](https://www.nyc.gov/site/doh/health/health-topics/respiratory-syncytial-virus.page)
- CDC Influenza: [https://www.cdc.gov/flu/index.htm](https://www.cdc.gov/flu/index.htm)
- CDC RSV: [https://www.cdc.gov/rsv/index.html](https://www.cdc.gov/rsv/index.html)
- CDC EV-D68: [https://www.cdc.gov/non-polio-enterovirus/about/ev-d68.html](https://www.cdc.gov/non-polio-enterovirus/about/ev-d68.html)
- 2018-2020 National EV-D68 Surveillance summary: [https://www.cdc.gov/mmwr/volumes/70/wr/mm7047a1.htm](https://www.cdc.gov/mmwr/volumes/70/wr/mm7047a1.htm)
Increased Respiratory Virus Activity, Especially Among Children, Early in the 2022-2023 Fall and Winter

Summary
The Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Network (HAN) Health Advisory about early, elevated respiratory disease incidence caused by multiple viruses occurring especially among children and placing strain on healthcare systems. Co-circulation of respiratory syncytial virus (RSV), influenza viruses, SARS-CoV-2, and others could place stress on healthcare systems this fall and winter. This early increase in disease incidence highlights the importance of optimizing respiratory virus prevention and treatment measures, including prompt vaccination and antiviral treatment, as outlined below.

Background
Many respiratory viruses with similar clinical presentations circulate year-round in the United States and at higher levels in fall and winter. In the past 2 years, respiratory disease activity has been dominated by SARS-CoV-2, and seasonal circulation of other respiratory viruses has been atypical or lower than pre-COVID-19 pandemic years. Currently, the U.S. is experiencing a surge and co-circulation of respiratory viruses other than SARS-CoV-2. CDC is tracking levels of respiratory syncytial virus (RSV), influenza, and rhinovirus/enterovirus (RV/EV) that are higher than usual for this time of year, especially among children, though RV/EV levels may have plateaued in recent weeks. SARS-CoV-2 also continues to circulate in all U.S. states.

RSV
CDC surveillance has shown an increase in RSV detections and RSV-associated emergency department visits and hospitalizations in all but two U.S. Department of Health and Human Services (HHS) regions (regions 4 and 6), with some regions already near the seasonal peak levels typically observed in December or January. This year, rates of RSV-associated hospitalizations began to increase during late spring and continued to increase through the summer and into early fall. Preliminary data from October 2022 show that weekly rates of RSV-associated hospitalizations among children younger than 18 years old are higher than rates observed during similar weeks in recent years. While RSV activity appears to be plateauing in some places, the timing, intensity, and severity of the current RSV season are uncertain.

Influenza
CDC has been tracking early and increasing influenza activity in recent weeks. The highest levels of influenza activity have been found in the southeast and south-central parts of the country. The most common viruses identified to date have been influenza A(H3N2) viruses, with most infections occurring in children and young adults. Cumulative influenza-associated hospitalization rates for children (age 0-4 years and 5-17 years) and all ages combined are notably higher compared to the same time periods during previous seasons since 2010–2011. Although the timing, intensity, and severity of the 2022–2023 influenza season are uncertain, CDC anticipates continued high-level circulation of influenza viruses this fall and winter.

SARS-CoV-2
CDC data are available to monitor COVID-19 community levels, which are based on hospitalization and case data and can be used to track SARS-CoV-2 activity. SARS-CoV-2 activity is expected to increase in the winter as has been observed in previous years.
years. Rates of COVID-19-associated hospitalizations among all age groups including children have decreased since August, but rates in infants younger than 6 months remain higher than in other pediatric age groups and higher than in all adult age groups except those 65 years and older. CDC expects continued high-level circulation of SARS-CoV-2 this fall and winter.

**Recommendations for Healthcare Providers**

CDC recommends that healthcare providers offer prompt vaccination against influenza and COVID-19 to all eligible people aged 6 months and older who are not up to date. Vaccination can prevent hospitalization and death associated with influenza and SARS-CoV-2 viruses.

Influenza vaccines have been updated for the current season (1). Of influenza A(H3N2) viruses that have been analyzed in the United States since May 2022, most A(H3N2) viruses are genetically and antigenically closely related to the updated A(H3N2) vaccine component. These data suggest influenza vaccination this season should offer protection against the predominant A(H3N2) viruses to date.

Currently approved SARS-CoV-2 bivalent mRNA booster doses for use in patients 5 years of age and older offer protection against both the ancestral SARS-CoV-2 virus and the currently predominant Omicron BA.4 and BA.5 subvariants that cause COVID-19. Emerging evidence suggests that COVID-19 vaccination provides some protection against multisystem inflammatory syndrome in children (MIS-C) and against post-COVID-19 conditions, and that vaccination among persons with post-COVID-19 conditions might help reduce their symptoms (2).

To prevent RSV-associated hospitalizations, eligible high-risk children should receive palivizumab treatment in accordance with AAP guidelines. In brief, children eligible for palivizumab include infants prematurely born at less than 29 weeks gestation, children younger than 2 years of age with chronic lung disease or hemodynamically significant congenital heart disease, and children with suppressed immune systems or neuromuscular disorders.

While vaccination is the primary means for preventing influenza and COVID-19, antiviral medications are important adjuncts used to treat illness in persons with severe illness and those at increased risk for complications. Both influenza and COVID-19 antiviral medications are most effective in reducing complications when treatment is started as early as possible after symptom onset.

**Specific Considerations for Healthcare Providers**

1. **Recommend and offer vaccinations against influenza and COVID-19 for all eligible persons aged 6 months or older**

   Anyone who has not received an influenza vaccine this season or who is not up to date with COVID-19 vaccination should be vaccinated now. Influenza and COVID-19 vaccines can be administered at the same visit. Vaccination is the best way to reduce the chance of illness and complications, including those resulting in hospitalization and death, from influenza and COVID-19. For the 2022-2023 influenza season, CDC recommends influenza vaccination with a licensed age-appropriate influenza vaccine for all people months and older (3). For COVID-19, CDC recommends that everyone 6 months and older complete a primary series of COVID-19 vaccines (4). In addition, CDC recommends that people 5 years and older receive one updated (bivalent) booster, if it has been at least 2 months since their last COVID-19 vaccine dose, whether that was a primary series or original (monovalent) booster (4). This recommendation includes people who have received more than one original (monovalent) booster. To date, uptake of both the current seasonal influenza vaccine and COVID-19 booster vaccines remains suboptimal (5, 6, 7).

   For COVID-19, preexposure prophylaxis with EVUSHELDTM, a monoclonal antibody, may help prevent COVID-19 in persons 12 years and older who are moderately to severely immunocompromised who might not mount an adequate immune response after COVID-19 vaccination, as well as persons for whom COVID-19 vaccination is not recommended because of their personal risk for severe adverse reactions. These guidelines may be updated based on circulation of variants with reduced susceptibility to monoclonal antibodies.

2. **Use diagnostic testing to guide treatment and clinical management**

   With multiple co-circulating respiratory viruses, particularly influenza and SARS-CoV-2, for which there are antiviral options recommended for specific groups, diagnostic testing can guide treatment and management to improve patients’ clinical course and outcomes. Diagnostic testing should be considered for patients with suspected respiratory virus infections, particularly among hospitalized patients, those with factors placing persons at high risk for severe outcomes from flu and COVID-19, and those with severe or progressive illness. Molecular assays are recommended when testing for RSV, influenza,
SARS-CoV-2, and other respiratory viruses in hospitalized patients with suspected respiratory virus infections, and multiplex respiratory testing should be considered since multiple respiratory viruses may cause severe illness. Information to assist clinicians about when to consider respiratory virus testing is available at Information for Clinicians on Influenza Virus Testing, Respiratory Syncytial Virus for Healthcare Professionals, and COVID-19 Testing: What You Need to Know. Information on RV/EV, EV-D68 testing was described in detail in a HAN Health Advisory released on September 9, 2022.

3. Treat patients with suspected or confirmed influenza who meet clinical criteria with influenza antivirals

CDC recommends influenza antiviral treatment as early as possible for any patient with confirmed or suspected influenza who is: a) hospitalized; b) an outpatient at higher risk for influenza complications; or c) an outpatient with severe, complicated, or progressive illness. Treatment with influenza antivirals has been shown to be safe and have clinical and public health benefit for both children and adults. Evidence from observational studies, randomized controlled trials, and meta-analyses of randomized controlled trials shows influenza antivirals reduce illness and severe outcomes of influenza (8, 9, 10, 11, 12). Clinical benefit is greatest when antiviral treatment is administered as early as possible after illness onset (ideally within 48 hours), although antiviral treatment initiated later than 48 hours after illness onset can still be beneficial for some patients (e.g., outpatients at increased risk for complications and hospitalized patients). Clinicians should not wait for laboratory confirmation to decide when to start influenza antiviral treatment in patients with suspected influenza.

Oral oseltamivir (generic formulation or Tamiflu®) is the recommended antiviral for outpatients with severe, complicated, or progressive illness and for hospitalized influenza patients. Oral baloxavir marboxil (Xofluza®) is approved by the U.S. Food and Drug Administration (FDA) for treating acute uncomplicated influenza in people 5 years and older who are otherwise healthy or in people 12 years and older who are at high risk of developing influenza-related complications. Oseltamivir is available as both an oral suspension and as capsules, whereas baloxavir is available only as tablets in the United States this fall and winter. Inhaled zanamivir and intravenous peramivir are less commonly used influenza antiviral medications. There is additional information on influenza antiviral medications for clinicians on the CDC website.

4. Treat outpatients and hospitalized patients with confirmed SARS-CoV-2 infection who are at increased risk for severe illness and meet age- and weight-eligibility requirements

COVID-19 antiviral agents reduce risk for hospitalization and death when administered soon after diagnosis. The antiviral medications nirmatrelvir and ritonavir (Paxlovid) or remdesivir (Veklury) are the preferred treatment options for COVID-19 in patients with mild to moderate illness who are at increased risk for severe illness, including older adults, unvaccinated persons, and those with certain medical conditions (14). The antiviral medication molnupiravir (Lagevrio) and monoclonal antibody bebtelovimab are alternative treatment options when Paxlovid and Veklury are contraindicated or not available. Additional information is available about treatment options for hospitalized adults and children and outpatient adults and children. Guidelines may be updated based on information about susceptibility of circulating SARS-CoV-2 variants.

5. Resources for patient education

In addition to practicing everyday prevention methods, like avoiding close contact with people who are sick, staying home when sick, covering coughs and sneezes, and hand washing, there are additional considerations for patients to help control the spread of and treat influenza, RSV, and COVID-19.

For patients and the general public who would like to know more about RSV, and clinicians who would like to learn about the impact of RSV infections among older adults, see Older Adults are at High Risk for Severe RSV Infection. Materials describing RSV prevention information in English and Spanish are also available.

Only about half of the U.S. population receives an annual influenza vaccine for various reasons, including misinformation about vaccination. Patient education materials are available at the Seasonal Flu Partner Resources Center. In addition, results from unpublished CDC qualitative research shows that many people are not aware that there are drugs to treat influenza illness. A fact sheet for patients is available.

Symptoms of COVID-19, options when experiencing symptoms (including getting tested for COVID-19 and isolation guidance), when to seek emergency medical attention, and differences between influenza and COVID-19 are described here: Symptoms of COVID-19 | CDC. CDC also provides easy-to-read COVID-19 materials.

For More Information
RSV

- RSV Information for Healthcare Providers
- RSV Trends and Surveillance
- RSV Symptoms and Care

Influenza

- Summary of Influenza Antiviral Treatment Recommendations for Clinicians
- Information for Clinicians on Influenza Virus Testing
- Interim Guidance for Influenza Outbreak Management in Long-Term Care Facilities
- Influenza Preventive Steps

COVID-19

- CDC COVID-19 Data Tracker
- NIH COVID-19 Treatment Guidelines
- COVID-19: People with Certain Medical Conditions
- COVID-19: Test to Treat Locator
- Indicators for Monitoring COVID-19 Community Levels and Making Public Health Recommendations

Rhinovirus/Enterovirus

- Severe Respiratory Illnesses Associated with Rhinoviruses and/or Enteroviruses Including EV-D68 – Multistate, 2022
- Increase in Acute Respiratory Illnesses Among Children and Adolescents Associated with Rhinoviruses and Enteroviruses, Including Enterovirus D68 — United States, July–September 2022

References


The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing and controlling diseases and injuries; enhances health decisions by providing credible information on critical health issues; and promotes healthy living through strong partnerships with local, national and international organizations.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

HAN Message Types
- **Health Alert**: Conveys the highest level of importance; warrants immediate action or attention.
- **Health Advisory**: Provides important information for a specific incident or situation; may not require immediate action.
- **Health Update**: Provides updated information regarding an incident or situation; unlikely to require immediate action.
- **Info Service**: Provides general information that is not necessarily considered to be of an emergent nature.

###
This message was distributed to state and local health officers, state and local epidemiologists, state and local laboratory directors, public information officers, HAN coordinators, and clinician organizations.

###

Additional Resources
- [HAN Archive By Year](#)
- [HAN Types](#)
- [Sign Up for HAN Email Updates](#)
- [HAN Jurisdictions](#)

Last Reviewed: November 4, 2022